Alk-Abello A/S

ALK B

Equity

ISIN DK0061802139 / Valor 117689788

Nasdaq Copenhagen Equities (2026-09-04)

DKK 208.80-0.19%

Alk-Abello A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Alk-Abello A/S is a Danish pharmaceutical company specializing in the development and production of allergy immunotherapy products. The company is committed to advancing long-term allergy treatment and aims to establish a leading position in the management of food allergies and anaphylaxis. Alk-Abello's strategic focus includes expanding its portfolio of respiratory allergy tablets and enhancing its pediatric coverage. The company is also exploring partnerships to accelerate the commercial adoption of its products across various markets. By prioritizing innovation and optimizing its operations, Alk-Abello seeks to address unmet needs in adjacent allergic conditions. The company emphasizes cultivating its organizational capabilities to foster a high-performance culture and improve access to allergy care.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and growth

Q4 2025 revenue DKK 1,733m (+17% l.c.); FY 2025 revenue DKK 6,312m (+15% l.c.), driven by double-digit growth across regions and expanding patient/prescriber bases.

Profitability (EBIT)

Q4 2025 EBIT DKK 387m (+88%) with a 22% margin. FY 2025 EBIT DKK 1,654m (+53%) with a 26% margin, reflecting higher sales, gross margin improvements and controlled cost increases.

Product performance

Tablets: Q4 DKK 910m (+15%); FY DKK 3,335m (+17%). SCIT/SLIT drops: Q4 DKK 607m (+11%); FY DKK 2,145m (+5%). Anaphylaxis & other: Q4 DKK 216m (+50%); FY DKK 832m (+34%), driven by Jext® and neffy®.

Cash flow and balance sheet

Free cash flow turned positive at DKK 1,432m (vs -204m prior), helped by higher earnings and an upfront payment from the new Chinese partnership with GenSci. Net interest‑bearing debt at end-2025 was DKK -822m (net cash); NIBD/EBITDA -0.4.

Shareholder remuneration

The Board recommends resuming dividends: DKK 355m for 2025 (≈30% of net profit after tax), equating to DKK 1.6 per share, and proposes a new programme targeting distribution of ~30% of net profit after tax going forward.

2026 outlook

ALK expects continued double‑digit organic revenue growth of 11–15% (l.c.) in 2026 and an EBIT margin of around 25%, while reinvesting part of the operational leverage into strategic growth initiatives.

Strategy and pipeline

The Allergy+ strategy is cited as performing well: strong paediatric tablet launches (ACARIZAX®, ITULAZAX®), ongoing neffy® rollouts, progress with partners (GenSci, ARS Pharma, Shionogi/Torii), and a peanut SLIT tablet Phase 2 topline readout expected in Q2 2026.

Summarized from source with an LLMView Source

Key figures

1.56%1Y

155%3Y

33.2%5Y

Performance

26.6%1Y

33.0%3Y

36.9%5Y

Volatility